<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120639</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-17774</org_study_id>
    <secondary_id>SU-04202010-5726</secondary_id>
    <secondary_id>BRN0012</secondary_id>
    <secondary_id>IRB-17774</secondary_id>
    <nct_id>NCT01120639</nct_id>
  </id_info>
  <brief_title>Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform</brief_title>
  <acronym>Tx-Treatment</acronym>
  <official_title>A Phase 1-2 Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and effectiveness of a combination
      treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved
      chemotherapy drug temozolomide
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To determine the maximum tolerated dose (MTD), based on acute CNS toxicity
      at 30 days, of hypofractionated radiotherapy given in 5 fractions with temozolomide for the
      treatment of glioblastoma multiforme.

      Secondary Objectives:

        1. Assess the short- and long-term adverse effects.

        2. Determine the radiographic response rate.

        3. Determine the overall survival rate.

        4. Assess quality of life during treatment

      To determine the maximum tolerated dose (MTD) of hypofractionated (5 fractions) radiotherapy
      with temozolomide for the treatment of glioblastoma multiforme, patients will be evaluated by
      a multi-disciplinary team composed of radiation oncologists, neurosurgeons, and
      neuro-oncologists to assess for their eligibility. Patient's oncologic history, presenting
      symptoms, physical examination, pathology, and imaging studies will be reviewed. Patients
      will be evaluated for surgical candidacy and resectability. Patients who are surgical
      candidates will undergo a surgical resection prior to radiotherapy. Patients whose tumors are
      unresectable or are not good surgical candidates will undergo a biopsy for tissue diagnosis.
      Radiation will be delivered in five fractions.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose-escalation with 2-level stratification</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>30 days</time_frame>
    <description>The maximum-tolerated dose (MTD) of study treatment (temozolomid plus hypofractionated radiotherapy administered as 5 fractions) is defined as either:
The highest radiation dose per protocol, or
The radiation dose at which dose-limiting toxicities (DLTs) occurred in ≥ 2 of 3 participants at a dose level, and/or ≥ 2 of 6 participants, at a dose level.
Dose-limiting toxicity (DLT) was defined as a treatment-related (with possible, probable or definite attribution) Grade 3 to 5 CNS toxicity [Common Terminology Criteria for Adverse Events (CTCAE) v4] occurring within 30 days of stereotactic radiosurgery (SRS).
The non-stratified outcome is reported as the number of DLTs observed in by radiation dose and by strata (Planning Target Volume (PTV) &lt; 60 cm³ and from 60 to 150 cm³).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Acute Toxicity Within 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Acute toxicity is defined as treatment-related adverse events that occur within 30 days of receiving radiotherapy. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 is used to grade adverse events. The non-stratified outcome is reported as number of treatment-related adverse events observed for each radiotherapy dose level.
Acute toxicity is based on radiotherapy dose level not tumor volume, and is reported by radiotherapy dose level only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Toxicity After More Than 30 Days</measure>
    <time_frame>12 months</time_frame>
    <description>Long-term toxicity is defined as treatment-related adverse events (any grade or any Body System) that occur ≥ 30 days after receiving radiotherapy. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 is used to grade adverse events. The non-stratified outcome is reported as number of treatment-related adverse events observed for each dose level.
Long-term toxicity is based on radiotherapy dose level not tumor volume, and is reported by radiotherapy dose level only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Radiographic Response</measure>
    <time_frame>6 months</time_frame>
    <description>Radiographic response rate was assessed following radiotherapy until disease progression. Response is considered to be the sum and proportion participants that achieved a complete response (CR); partial response (PR); or minor response (MR). The outcome is expressed as a number without dispersion for each cohort.
CR: Tumor is no longer detected by computed tomography (CT) or magnetic resonance imaging (MRI).
PR: Decrease in the product of the two greatest diameters &gt; 50%, as determined by CT or MRI, with no new lesions, and the same or lower dose of dexamethasone.
MR: Decrease in the product of the two greatest diameters &lt; 50%, as determined by CT or MRI, and neither PR nor PD.
PD: New tumor lesion, or &gt; 25% increase in the product of the two greatest diameters of target lesion, as determined by CT or MRI, provided that within 2 months of completion of radiotherapy, the participant has not had a decrease in steroid dose since the last evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>18 Months.</time_frame>
    <description>Progression-free survival (PFS) following radiotherapy, measured in months. Progressive disease (PD) is defined as: New tumor lesion, or &gt; 25% increase in the product of the 2 greatest diameters of target lesion, as determined by computed tomography (CT) or magnetic resonance imaging (MRI), provided that within 2 months of completion of radiotherapy, the participant has not had a decrease in steroid dose since the last evaluation. The outcome is expressed as the median with 95% confidence interval for each cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>20 Months.</time_frame>
    <description>Overall survival (OS) was assessed as those participants remaining alive with any tumor status following radiotherapy after 20 months. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and expressed as the median value with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life by European Organisation for Research and Treatment of Cancer (EORTC-QLQ C30) Survey</measure>
    <time_frame>12 Months</time_frame>
    <description>European Organization for Research and Treatment of Cancer (EORTC-QLQ C30) quality of life surveys were administered at study entry and 12 months after treatment initiation to assess health-related quality of life (HR-QOL). The EORTC-QLQ C30 survey has 30 questions and responses are on scale of 1 to 4 with 1 indicating &quot;not at all&quot; and 4 indicating &quot;very much&quot;. The total score can range from 30 to 120. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and is expressed as the mean of the difference from baseline to 12 months, with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life by Brain-20 Survey</measure>
    <time_frame>12 months</time_frame>
    <description>Brain-20 (BN-20) quality of life surveys were administered at study entry and 12 months after treatment initiation to assess health-related quality of life (HR-QOL). The Brain-20 (BN-20) quality of life survey has 20 questions and responses are on scale of 1 to 4 with 1 indicating &quot;not at all&quot; (most favorable) and 4 indicating &quot;very much&quot; (least favorable). The total score can range from 20 to 80, and the result is expressed as the difference from baseline (study entry) to 12 months after the start of treatment. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and expressed as the mean with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life by MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Survey</measure>
    <time_frame>12 months</time_frame>
    <description>MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) quality of life surveys were administered at study entry and 12 months after treatment initiation to assess health-related quality of life (HR-QOL). MDASI-BT quality of life survey has 23 questions and responses are on scale of 0 to 10 with 0 indicating &quot;did not interfere&quot; (most favorable) and 10 indicating &quot;interfered completely&quot; (least favorable). A participant's overall score is computed as the mean of that participant's individual scores, and can range 0 to 10. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and expressed as the mean difference from baseline with 95% confidence interval. A positive value for the mean indicates worsening quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Failure Analysis</measure>
    <time_frame>18 months</time_frame>
    <description>Treatment failure in individual participants, ie, tumor recurrence or metastasis, can be described by the location relative to the first treatment failure (ie, infield, marginal, or distal), as further defined below.
Failure pattern is defined as tumor recurrence or metastasis relative to the primary lesion that is
Infield: at tumor or within 5 mm
Marginal: &gt; 5 mm or ≤ 20 mm from tumor
Distal: &gt; 20 mm from tumor
The outcome will be reported as the number of participants who failed treatment for each type of failure, ie, infield, marginal, or distal failure.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Cancer of Brain and Nervous System</condition>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery (25 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery (30 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery (35 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery (40 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.</description>
    <arm_group_label>Stereotactic Radiosurgery (25 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_label>Stereotactic Radiosurgery (30 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_label>Stereotactic Radiosurgery (35 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_label>Stereotactic Radiosurgery (40 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stereotactic Radiosurgery (SRS)</intervention_name>
    <description>Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
    <arm_group_label>Stereotactic Radiosurgery (25 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_label>Stereotactic Radiosurgery (30 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_label>Stereotactic Radiosurgery (35 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <arm_group_label>Stereotactic Radiosurgery (40 Gray x 5 fractions)+Temozolomide</arm_group_label>
    <other_name>Hypofractionated stereotactic radiosurgery (h-SRS)</other_name>
    <other_name>Hypofractionated stereotactic radiotherapy</other_name>
    <other_name>Cyberknife surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed newly diagnosed glioblastoma multiforme. Diagnosis must
             be made by surgical biopsy or excision

          -  The tumor must be supratentorial in location

          -  The planning target volume (tumor plus margin) must measure ≤ 150 cm^3 in volume

          -  Age ≥ 18 years

          -  Life expectancy of at least 12 weeks

          -  Patient must have adequate organ function to tolerate temozolomide (details in the
             protocol)

        Exclusion Criteria:

          -  Patients who have previously been treated with brain irradiation to the region that
             would result in overlap of the radiation fields

          -  Tumor foci detected below the tentorium

          -  Multifocal disease or leptomeningeal spread

          -  Prior allergic reaction to the study drugs involved in this protocol

          -  Patients with pacemaker will be allowed to undergo CT instead of MRI

          -  Pediatric patients (age &lt; 18), pregnant women, and nursing patients will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Gerard Soltys, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2010</study_first_posted>
  <results_first_submitted>February 7, 2019</results_first_submitted>
  <results_first_submitted_qc>July 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2019</results_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Scott Soltys</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 3, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT01120639/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="P2">
          <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="P3">
          <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="P4">
          <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="B2">
          <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="B3">
          <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="B4">
          <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="5.8"/>
                    <measurement group_id="B2" value="61.4" spread="8.3"/>
                    <measurement group_id="B3" value="62.8" spread="10.0"/>
                    <measurement group_id="B4" value="67.1" spread="8.6"/>
                    <measurement group_id="B5" value="65.9" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Dose-limiting Toxicities (DLTs)</title>
        <description>The maximum-tolerated dose (MTD) of study treatment (temozolomid plus hypofractionated radiotherapy administered as 5 fractions) is defined as either:
The highest radiation dose per protocol, or
The radiation dose at which dose-limiting toxicities (DLTs) occurred in ≥ 2 of 3 participants at a dose level, and/or ≥ 2 of 6 participants, at a dose level.
Dose-limiting toxicity (DLT) was defined as a treatment-related (with possible, probable or definite attribution) Grade 3 to 5 CNS toxicity [Common Terminology Criteria for Adverse Events (CTCAE) v4] occurring within 30 days of stereotactic radiosurgery (SRS).
The non-stratified outcome is reported as the number of DLTs observed in by radiation dose and by strata (Planning Target Volume (PTV) &lt; 60 cm³ and from 60 to 150 cm³).</description>
        <time_frame>30 days</time_frame>
        <population>Participants receiving each radiotherapy level were stratified by tumor size.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose-limiting Toxicities (DLTs)</title>
          <description>The maximum-tolerated dose (MTD) of study treatment (temozolomid plus hypofractionated radiotherapy administered as 5 fractions) is defined as either:
The highest radiation dose per protocol, or
The radiation dose at which dose-limiting toxicities (DLTs) occurred in ≥ 2 of 3 participants at a dose level, and/or ≥ 2 of 6 participants, at a dose level.
Dose-limiting toxicity (DLT) was defined as a treatment-related (with possible, probable or definite attribution) Grade 3 to 5 CNS toxicity [Common Terminology Criteria for Adverse Events (CTCAE) v4] occurring within 30 days of stereotactic radiosurgery (SRS).
The non-stratified outcome is reported as the number of DLTs observed in by radiation dose and by strata (Planning Target Volume (PTV) &lt; 60 cm³ and from 60 to 150 cm³).</description>
          <population>Participants receiving each radiotherapy level were stratified by tumor size.</population>
          <units>Number of DLT observed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Planning Target Volume (PTV) &lt; 60 cm³</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning Target Volume (PTV) 60 to 150 cm³</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Acute Toxicity Within 30 Days</title>
        <description>Acute toxicity is defined as treatment-related adverse events that occur within 30 days of receiving radiotherapy. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 is used to grade adverse events. The non-stratified outcome is reported as number of treatment-related adverse events observed for each radiotherapy dose level.
Acute toxicity is based on radiotherapy dose level not tumor volume, and is reported by radiotherapy dose level only.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Acute Toxicity Within 30 Days</title>
          <description>Acute toxicity is defined as treatment-related adverse events that occur within 30 days of receiving radiotherapy. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 is used to grade adverse events. The non-stratified outcome is reported as number of treatment-related adverse events observed for each radiotherapy dose level.
Acute toxicity is based on radiotherapy dose level not tumor volume, and is reported by radiotherapy dose level only.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTCAE Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Toxicity After More Than 30 Days</title>
        <description>Long-term toxicity is defined as treatment-related adverse events (any grade or any Body System) that occur ≥ 30 days after receiving radiotherapy. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 is used to grade adverse events. The non-stratified outcome is reported as number of treatment-related adverse events observed for each dose level.
Long-term toxicity is based on radiotherapy dose level not tumor volume, and is reported by radiotherapy dose level only.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Toxicity After More Than 30 Days</title>
          <description>Long-term toxicity is defined as treatment-related adverse events (any grade or any Body System) that occur ≥ 30 days after receiving radiotherapy. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 is used to grade adverse events. The non-stratified outcome is reported as number of treatment-related adverse events observed for each dose level.
Long-term toxicity is based on radiotherapy dose level not tumor volume, and is reported by radiotherapy dose level only.</description>
          <units>Number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTCAE Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All grades</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Radiographic Response</title>
        <description>Radiographic response rate was assessed following radiotherapy until disease progression. Response is considered to be the sum and proportion participants that achieved a complete response (CR); partial response (PR); or minor response (MR). The outcome is expressed as a number without dispersion for each cohort.
CR: Tumor is no longer detected by computed tomography (CT) or magnetic resonance imaging (MRI).
PR: Decrease in the product of the two greatest diameters &gt; 50%, as determined by CT or MRI, with no new lesions, and the same or lower dose of dexamethasone.
MR: Decrease in the product of the two greatest diameters &lt; 50%, as determined by CT or MRI, and neither PR nor PD.
PD: New tumor lesion, or &gt; 25% increase in the product of the two greatest diameters of target lesion, as determined by CT or MRI, provided that within 2 months of completion of radiotherapy, the participant has not had a decrease in steroid dose since the last evaluation.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Radiographic Response</title>
          <description>Radiographic response rate was assessed following radiotherapy until disease progression. Response is considered to be the sum and proportion participants that achieved a complete response (CR); partial response (PR); or minor response (MR). The outcome is expressed as a number without dispersion for each cohort.
CR: Tumor is no longer detected by computed tomography (CT) or magnetic resonance imaging (MRI).
PR: Decrease in the product of the two greatest diameters &gt; 50%, as determined by CT or MRI, with no new lesions, and the same or lower dose of dexamethasone.
MR: Decrease in the product of the two greatest diameters &lt; 50%, as determined by CT or MRI, and neither PR nor PD.
PD: New tumor lesion, or &gt; 25% increase in the product of the two greatest diameters of target lesion, as determined by CT or MRI, provided that within 2 months of completion of radiotherapy, the participant has not had a decrease in steroid dose since the last evaluation.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Planning Target Volume (PTV) &lt;60 CM3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning Target Volume (PTV) 60-150CM3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival (PFS) following radiotherapy, measured in months. Progressive disease (PD) is defined as: New tumor lesion, or &gt; 25% increase in the product of the 2 greatest diameters of target lesion, as determined by computed tomography (CT) or magnetic resonance imaging (MRI), provided that within 2 months of completion of radiotherapy, the participant has not had a decrease in steroid dose since the last evaluation. The outcome is expressed as the median with 95% confidence interval for each cohort.</description>
        <time_frame>18 Months.</time_frame>
        <population>Participants who have not progresses and have not reached reached 18 months post-treatment are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free survival (PFS) following radiotherapy, measured in months. Progressive disease (PD) is defined as: New tumor lesion, or &gt; 25% increase in the product of the 2 greatest diameters of target lesion, as determined by computed tomography (CT) or magnetic resonance imaging (MRI), provided that within 2 months of completion of radiotherapy, the participant has not had a decrease in steroid dose since the last evaluation. The outcome is expressed as the median with 95% confidence interval for each cohort.</description>
          <population>Participants who have not progresses and have not reached reached 18 months post-treatment are not included.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Planning Target Volume (PTV) &lt;60 CM3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="7.6" upper_limit="21.5"/>
                    <measurement group_id="O2" value="10.5" lower_limit="8.7" upper_limit="11.7"/>
                    <measurement group_id="O3" value="33.5" lower_limit="18.2" upper_limit="64.3"/>
                    <measurement group_id="O4" value="3.9" lower_limit="1.7" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning Target Volume (PTV) 60-150CM3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="3.2" upper_limit="23.3"/>
                    <measurement group_id="O2" value="6.5" lower_limit="2.0" upper_limit="9.5"/>
                    <measurement group_id="O3" value="8.8" lower_limit="5.6" upper_limit="17.6"/>
                    <measurement group_id="O4" value="4.0" lower_limit="1.7" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival (OS) was assessed as those participants remaining alive with any tumor status following radiotherapy after 20 months. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and expressed as the median value with 95% confidence interval.</description>
        <time_frame>20 Months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival (OS) was assessed as those participants remaining alive with any tumor status following radiotherapy after 20 months. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and expressed as the median value with 95% confidence interval.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Planning Target Volume (PTV) &lt;60 CM3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="14.9" upper_limit="27.8"/>
                    <measurement group_id="O2" value="19.9" lower_limit="14.8" upper_limit="62.4"/>
                    <measurement group_id="O3" value="48.3" lower_limit="33.5" upper_limit="64.4"/>
                    <measurement group_id="O4" value="10.2" lower_limit="1.7" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning Target Volume (PTV) 60-150CM3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.7" upper_limit="35.4"/>
                    <measurement group_id="O2" value="11.3" lower_limit="10.9" upper_limit="16.1"/>
                    <measurement group_id="O3" value="17.6" lower_limit="8.8" upper_limit="21.4"/>
                    <measurement group_id="O4" value="11.6" lower_limit="5.3" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life by European Organisation for Research and Treatment of Cancer (EORTC-QLQ C30) Survey</title>
        <description>European Organization for Research and Treatment of Cancer (EORTC-QLQ C30) quality of life surveys were administered at study entry and 12 months after treatment initiation to assess health-related quality of life (HR-QOL). The EORTC-QLQ C30 survey has 30 questions and responses are on scale of 1 to 4 with 1 indicating &quot;not at all&quot; and 4 indicating &quot;very much&quot;. The total score can range from 30 to 120. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and is expressed as the mean of the difference from baseline to 12 months, with 95% confidence interval.</description>
        <time_frame>12 Months</time_frame>
        <population>Some participants did not contribute one or both of the baseline (study entry) and 12-month assessments, and the outcome (difference from baseline / study entry to 12 months after the start of treatment could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life by European Organisation for Research and Treatment of Cancer (EORTC-QLQ C30) Survey</title>
          <description>European Organization for Research and Treatment of Cancer (EORTC-QLQ C30) quality of life surveys were administered at study entry and 12 months after treatment initiation to assess health-related quality of life (HR-QOL). The EORTC-QLQ C30 survey has 30 questions and responses are on scale of 1 to 4 with 1 indicating &quot;not at all&quot; and 4 indicating &quot;very much&quot;. The total score can range from 30 to 120. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and is expressed as the mean of the difference from baseline to 12 months, with 95% confidence interval.</description>
          <population>Some participants did not contribute one or both of the baseline (study entry) and 12-month assessments, and the outcome (difference from baseline / study entry to 12 months after the start of treatment could not be calculated.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Planning Target Volume (PTV) &lt;60 CM3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" lower_limit="-275.9" upper_limit="359.3"/>
                    <measurement group_id="O2" value="58.3" lower_limit="-16.3" upper_limit="132.9"/>
                    <measurement group_id="O3" value="80.5" lower_limit="28.4" upper_limit="132.6"/>
                    <measurement group_id="O4" value="53.3" lower_limit="14.2" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning Target Volume (PTV) 60-150CM3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" lower_limit="-13.1" upper_limit="96.4"/>
                    <measurement group_id="O2" value="52.7" lower_limit="0.68" upper_limit="104.8"/>
                    <measurement group_id="O3" value="44.4" lower_limit="20.5" upper_limit="68.3"/>
                    <measurement group_id="O4" value="51.3" lower_limit="13.7" upper_limit="89.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life by Brain-20 Survey</title>
        <description>Brain-20 (BN-20) quality of life surveys were administered at study entry and 12 months after treatment initiation to assess health-related quality of life (HR-QOL). The Brain-20 (BN-20) quality of life survey has 20 questions and responses are on scale of 1 to 4 with 1 indicating &quot;not at all&quot; (most favorable) and 4 indicating &quot;very much&quot; (least favorable). The total score can range from 20 to 80, and the result is expressed as the difference from baseline (study entry) to 12 months after the start of treatment. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and expressed as the mean with 95% confidence interval.</description>
        <time_frame>12 months</time_frame>
        <population>Some participants did not contribute one or both of the baseline (study entry) and 12-month assessments, and the outcome (difference from baseline / study entry to 12 months after the start of treatment could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life by Brain-20 Survey</title>
          <description>Brain-20 (BN-20) quality of life surveys were administered at study entry and 12 months after treatment initiation to assess health-related quality of life (HR-QOL). The Brain-20 (BN-20) quality of life survey has 20 questions and responses are on scale of 1 to 4 with 1 indicating &quot;not at all&quot; (most favorable) and 4 indicating &quot;very much&quot; (least favorable). The total score can range from 20 to 80, and the result is expressed as the difference from baseline (study entry) to 12 months after the start of treatment. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and expressed as the mean with 95% confidence interval.</description>
          <population>Some participants did not contribute one or both of the baseline (study entry) and 12-month assessments, and the outcome (difference from baseline / study entry to 12 months after the start of treatment could not be calculated.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Planning Target Volume (PTV) &lt;60 CM3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" lower_limit="-356.8" upper_limit="490.2"/>
                    <measurement group_id="O2" value="40.7" lower_limit="-70.8" upper_limit="152.2"/>
                    <measurement group_id="O3" value="18.5" lower_limit="-611.1" upper_limit="98.1"/>
                    <measurement group_id="O4" value="44.4" lower_limit="-8.0" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning Target Volume (PTV) 60-150CM3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="-1.4" upper_limit="82.9"/>
                    <measurement group_id="O2" value="55.5" lower_limit="-43.9" upper_limit="155.0"/>
                    <measurement group_id="O3" value="59.2" lower_limit="1.8" upper_limit="116.7"/>
                    <measurement group_id="O4" value="25.9" lower_limit="-9.1" upper_limit="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life by MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Survey</title>
        <description>MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) quality of life surveys were administered at study entry and 12 months after treatment initiation to assess health-related quality of life (HR-QOL). MDASI-BT quality of life survey has 23 questions and responses are on scale of 0 to 10 with 0 indicating &quot;did not interfere&quot; (most favorable) and 10 indicating &quot;interfered completely&quot; (least favorable). A participant's overall score is computed as the mean of that participant's individual scores, and can range 0 to 10. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and expressed as the mean difference from baseline with 95% confidence interval. A positive value for the mean indicates worsening quality of life.</description>
        <time_frame>12 months</time_frame>
        <population>Some participants did not contribute one or both of the baseline (study entry) and 12-month assessments, and the outcome (difference from baseline / study entry to 12 months after the start of treatment could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life by MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Survey</title>
          <description>MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) quality of life surveys were administered at study entry and 12 months after treatment initiation to assess health-related quality of life (HR-QOL). MDASI-BT quality of life survey has 23 questions and responses are on scale of 0 to 10 with 0 indicating &quot;did not interfere&quot; (most favorable) and 10 indicating &quot;interfered completely&quot; (least favorable). A participant's overall score is computed as the mean of that participant's individual scores, and can range 0 to 10. The outcome is stratified by Planning Target Volume (PTV) &lt; 60 cm³ or 60 to 150 cm³, and expressed as the mean difference from baseline with 95% confidence interval. A positive value for the mean indicates worsening quality of life.</description>
          <population>Some participants did not contribute one or both of the baseline (study entry) and 12-month assessments, and the outcome (difference from baseline / study entry to 12 months after the start of treatment could not be calculated.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Planning Target Volume (PTV) &lt;60 CM3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="-51.9" upper_limit="62.4"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-23.4" upper_limit="27.4"/>
                    <measurement group_id="O3" value="2.8" lower_limit="-5.0" upper_limit="10.7"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.2" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planning Target Volume (PTV) 60-150CM3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="0.5" upper_limit="6.9"/>
                    <measurement group_id="O2" value="3.2" lower_limit="-5.1" upper_limit="11.6"/>
                    <measurement group_id="O3" value="2.3" lower_limit="-3.0" upper_limit="7.6"/>
                    <measurement group_id="O4" value="3.6" lower_limit="0.5" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Failure Analysis</title>
        <description>Treatment failure in individual participants, ie, tumor recurrence or metastasis, can be described by the location relative to the first treatment failure (ie, infield, marginal, or distal), as further defined below.
Failure pattern is defined as tumor recurrence or metastasis relative to the primary lesion that is
Infield: at tumor or within 5 mm
Marginal: &gt; 5 mm or ≤ 20 mm from tumor
Distal: &gt; 20 mm from tumor
The outcome will be reported as the number of participants who failed treatment for each type of failure, ie, infield, marginal, or distal failure.</description>
        <time_frame>18 months</time_frame>
        <population>If the location of a participant's 1st treatment failure could not be determined, then a location assessment relative to any 2nd treatment failure can not done (null result), and for this reason, this analysis only includes participants for whom the location of the 1st treatment failure could be determined.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O3">
            <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
          <group group_id="O4">
            <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
            <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure Analysis</title>
          <description>Treatment failure in individual participants, ie, tumor recurrence or metastasis, can be described by the location relative to the first treatment failure (ie, infield, marginal, or distal), as further defined below.
Failure pattern is defined as tumor recurrence or metastasis relative to the primary lesion that is
Infield: at tumor or within 5 mm
Marginal: &gt; 5 mm or ≤ 20 mm from tumor
Distal: &gt; 20 mm from tumor
The outcome will be reported as the number of participants who failed treatment for each type of failure, ie, infield, marginal, or distal failure.</description>
          <population>If the location of a participant's 1st treatment failure could not be determined, then a location assessment relative to any 2nd treatment failure can not done (null result), and for this reason, this analysis only includes participants for whom the location of the 1st treatment failure could be determined.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-Field</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="E2">
          <title>Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="E3">
          <title>Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
        <group group_id="E4">
          <title>Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide</title>
          <description>Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) &lt; 60 cm³ vs 60 to 150 cm³.
Temozolomide: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS): Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders-Other, altered mental state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Edema cerebral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, ressection of recurrent tumor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nervous system disorders -Other, necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nervous system disorders -Other, aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scott Soltys (Associate Professor of Radiation Oncology)</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-724-1569</phone>
      <email>sgsoltys@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

